4570 Immuno-Biological Laboratories Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4570

TSE Growth

Immuno-Biological Laboratories Co., Ltd.

445

JPY

-7

(-1.55%)

Dec 23, 3:30 pm JST

2.84

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

440

Dec 23, 8:05 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	602	-240	-310	-318	-34.2	0	May 14, 2021	J-GAAP
Mar, 2022	647	-122	-243	-258	-27.8	0	May 13, 2022	J-GAAP
Mar, 2023	794	57	-149	-289	-31.1	0	May 12, 2023	J-GAAP
Mar, 2024	816	104	125	186	20.1	0	May 14, 2024	J-GAAP
Mar, 2025 Guidance	925	120	120	115	12.4	0	May 14, 2024	J-GAAP
YoY	+13.4%	+15.4%	-4.0%	-38.2%	-38.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 14, 2019	991	-391	-550	-565	0	J-GAAP
	Nov 8, 2019	670	-510	-640	-655	0	J-GAAP
	Mar 17, 2020	565	-650	-730	-745	0	J-GAAP
Results	May 14, 2020	576	-595	-678	-668	0	J-GAAP
Mar, 2021	May 14, 2020	Available in future release
	Aug 6, 2020
Results	May 14, 2021
Mar, 2022	May 14, 2021
	Mar 15, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Apr 27, 2023
Results	May 12, 2023
Mar, 2024	May 12, 2023
	May 10, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024	925	120	120	115	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2002	825	－	Available in future release
Mar, 2003	1,001	+21.3
Mar, 2004	1,086	+8.5
Mar, 2005	1,110	+2.2
Mar, 2006	1,502	+35.3
Mar, 2007	1,533	+2.1
Mar, 2008	1,288	-16.0
Mar, 2009	1,036	-19.6
Mar, 2010	1,059	+2.2
Mar, 2011	1,059	0.0
Mar, 2012	915	-13.6
Mar, 2013	800	-12.6
Mar, 2014	670	-16.3
Mar, 2015	729	+8.8
Mar, 2016	717	-1.6
Mar, 2017	741	+3.3
Mar, 2018	758	+2.3
Mar, 2019	781	+3.0
Mar, 2020	576	-26.2
Mar, 2021	602	+4.5
Mar, 2022	647	+7.5
Mar, 2023	794	+22.7
Mar, 2024	816	+2.8
Mar, 2025 Guidance	925	+13.4	120	+15.4	120	-4.0	12.4	-38.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	794	57	7.18	-23.63	-18.41	0.51	-31.1
Mar, 2024	816	104	12.8	15.88	12.19	0.53	20.1
Mar, 2025 Guidance	925	120	13.0	8.61	6.99	0.56	12.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,533	160	156	186	24.8
Fiscal Year	Mar, 2007	Mar, 2003	Mar, 2003	Mar, 2024	Mar, 2013

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	394	14	-55	-59	-6.4	0	May 13, 2022	J-GAAP
Oct - Mar, 2022	501	111	-20	-153	-16.5	0	May 12, 2023	J-GAAP
Oct - Mar, 2023	451	91	95	160	17.3	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	481	52	56	44	4.7	0	Nov 11, 2024	J-GAAP
YoY	+6.7%	-42.9%	-41.1%	-72.5%	-72.6%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-122	-248	-93	-155	143	449	26.33	J-GAAP
Mar, 2023	57	56	26	30	0	561	39.12	J-GAAP
Mar, 2024	104	109	133	-24	0	674	41.66	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	293	-54	-129	-136	-14.6	ー	Nov 4, 2022	J-GAAP
Apr - Sep, 2023	365	13	30	26	2.9	24.0	Nov 2, 2023	J-GAAP
Apr - Sep, 2024	444	68	64	71	7.7	53.3	Nov 11, 2024	J-GAAP
YoY	+21.6%	+423.1%	+113.3%	+173.1%	+166.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	261	72	62	60	6.5	27.6	Feb 6, 2023	J-GAAP
Jan - Mar, 2023	240	39	-82	-213	-22.9	16.3	May 12, 2023	J-GAAP
Apr - Jun, 2023	177	0	13	11	1.2	0.0	Aug 7, 2023	J-GAAP
Jul - Sep, 2023	188	13	17	15	1.7	6.9	Nov 2, 2023	J-GAAP
Oct - Dec, 2023	183	-3	-5	-6	-0.7	-1.6	Feb 2, 2024	J-GAAP
Jan - Mar, 2024	268	94	100	166	17.9	35.1	May 14, 2024	J-GAAP
Apr - Jun, 2024	229	51	56	51	5.5	22.3	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	215	17	8	20	2.2	7.9	Nov 11, 2024	J-GAAP
YoY	+14.4%	+30.8%	-52.9%	+33.3%	+30.1%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	159	-18.0	Available in future release
Jan - Mar, 2020	187	-7.9
Apr - Jun, 2020	116	+2.7
Jul - Sep, 2020	131	+12.0
Oct - Dec, 2020	167	+5.0
Jan - Mar, 2021	188	+0.5
Apr - Jun, 2021	125	+7.8
Jul - Sep, 2021	128	-2.3
Oct - Dec, 2021	195	+16.8
Jan - Mar, 2022	199	+5.9
Apr - Jun, 2022	156	+24.8
Jul - Sep, 2022	137	+7.0
Oct - Dec, 2022	261	+33.8
Jan - Mar, 2023	240	+20.6
Apr - Jun, 2023	177	+13.5
Jul - Sep, 2023	188	+37.2
Oct - Dec, 2023	183	-29.9
Jan - Mar, 2024	268	+11.7
Apr - Jun, 2024	229	+29.4
Jul - Sep, 2024	215	+14.4	17	+30.8	8	-52.9	2.2	+29.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	606	238	234	227	24.2
Fiscal Year	Dec, 2006	Dec, 2006	Dec, 2006	Dec, 2006	Mar, 2008

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	146.92	80.2	1,705	1,368	-3,720	0.17	May 13, 2022	J-GAAP
Mar, 2023	115.81	75.2	1,434	1,078	-4,009	0.22	May 12, 2023	J-GAAP
Mar, 2024	135.85	78.2	1,618	1,265	176	0.19	May 14, 2024	J-GAAP
Apr - Sep, 2024	ー	81.2	1,645	1,336	248	0.15	Nov 11, 2024	J-GAAP

Immuno-Biological Laboratories Co., Ltd.(4570) Financial Results